The oncosurgery approach to managing liver metastases from colorectal cancer: A multidisciplinary international consensus

Oncologist

Volumn 17, Issue 10, 2012, Pages 1225-1239

  Adam, René ^a   De Gramont, Aimery ^b   Figueras, Joan ^c   Guthrie, Ashley ^d   Kokudo, Norihiro ^e   Kunstlinger, Francis ^a   Loyer, Evelyne ^f   Poston, Graeme ^g   Rougier, Philippe ^h   Rubbia Brandt, Laura ⁱ   Sobrero, Alberto ^j   Tabernero, Josep ^k   Teh, Catherine ^l   Van Cutsem, Eric ^m   Vauthey, Jean Nicolas ^f  

^a HÔPITAL PAUL BROUSSE   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF TOKYO   (Japan)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j UNIVERSITY OF GENOA   (Italy)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l MAKATI MEDICAL CENTER   (Philippines)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Biochemotherapy; Chemotherapy; Colorectal cancer; Hepatectomy; Hepatobiliary multidisciplinary teams; Imaging; Liver metastases; Resection; Targeted treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PEGINTERFERON ALPHA2B;

ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG EFFICACY; ECHOGRAPHY; HUMAN; LIVER METASTASIS; LIVER RESECTION; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84868104706     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0121     Document Type: Article

References (150)

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008, Version 1.2, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10. Available at http://globocan.iarc.fr, accessed November 23, 2011.
2. Sung JJ, Lau JY, Goh KL et al. Increasing incidence of colorectal cancer in Asia: Implications for screening. Lancet Oncol 2005;6:871-876.
3. Nordlinger B, Van Cutsem E, Rougier P et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? Areport from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007;43:2037-2045.
4. Van den Eynde M, Hendlisz A. Treatment of colorectal liver metastases: A review. Rev Recent Clin Trials 2009;4:56-62.
5. Poston GJ, Figueras J, Giuliante F et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008;26:4828-4833.
6. Aloia TA, Adam R, Azoulay D et al. Outcome following hepatic resection of metastatic renal tumors: The Paul Brousse Hospital experience. HPB (Oxford) 2006; 8:100-105.
7. Ebell MH, Siwek J, Weiss BD et al. Strength of recommendation taxonomy (SORT):Apatient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004;69:548-556.
8. Floriani I, Torri V, Rulli E et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta-analysis. J Magn Reson Imaging 2010;31:19-31.
9. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: A meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010;257:674-684.
10. Selzner M, Hany TF, Wildbrett P et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027-1034; discussion 1035-1036.
11. Bartolotta TV, Taibbi A, MidiriMet al. Characterisation of focal liver lesions undetermined at grey-scale US: Contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent. Radiol Med 2010;115:714-731.
12. Kodama Y, Ng CS, WuTT et al. Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol 2007;188:1307-1312.
13. Reeder SB, Sirlin CB. Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am 2010;18:337-357, ix.
14. van Werven JR, Marsman HA, Nederveen AJ et al. Assessment of hepatic steatosis in patients undergoing liver resection: Comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy Radiology 2010;256:159-168.
15. Overman MJ, Maru DM, Charnsangavej C et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 2010;28:2549-2555.
16. Shin NY, Kim MJ, Lim JS et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 2012;22:864-871. doi: 10.1007/s00330-011-2333-x.
17. Zorzi D, Laurent A, Pawlik TM et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007;94:274-286.
18. Chami L, Lassau N, Malka D et al. Benefits of contrast-enhanced sonography for the detection of liver lesions: Comparison with histologic findings. AJR Am J Roentgenol 2008;190:683-690.
19. Leen E, Ceccotti P, Moug SJ et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: An essential investigation before resection? Ann Surg 2006;243: 236-240.
20. Necib H, Garcia C, Wagner A et al. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging. J Nucl Med 2011;52:354-361.
21. Hendlisz A, Golfinopoulos V, Garcia C et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol 2012;23:1687-1693. doi: 10.1093/annonc/mdr554.
22. Ruers TJ, Wiering B, van der Sijp JR et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: A randomized study. J Nucl Med 2009;50:1036-1041.
23. Wiering B, Adang EM, van der Sijp JR et al. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Nucl Med Commun 2010;31:938-944.
24. Moulton C, Levine MN, Law C et al. An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM). J Clin Oncol 2011;29(15 suppl):3520.
25. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008;371:1007-1016.
26. Adam R, Bhangui P, Poston G et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010;252:774-787.
27. Nordlinger B, Vauthey JN, Poston G et al. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 2010;9:212-218.
28. Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-3683.
29. Golfinopoulos V, Salanti G, Pavlidis N et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: A meta-analysis. Lancet Oncol 2007;8:898-911.
30. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004;240:644-657; discussion 657-658.
31. Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9249.
32. Ho WM, Ma B, Mok T et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: A multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol 2005;22:303-312.
33. Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933-939.
34. Adam R, Pascal G, Castaing D et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052-1061; discussion 1061-1064.
35. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as firstline treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25: 1670-1676.
36. Elias D, Lasser P, Rougier P et al. Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg 1995;180:213-219.
37. Goéré D, Deshaies I, De Baere T et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010;251:686-691.
38. Bouchahda M, Adam R, Giacchetti S et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 2009;115:4990-4999.
39. Bokemeyer C, Bondarenko I, MakhsonAet al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
40. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
41. Van Cutsem E, Köhne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
42. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal can-cer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-2114.
43. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
44. Garufi C, Torsello A, Tumolo S et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010;103:1542-1547.
45. Tveit K, Guren T, Glimelius B et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 2011;29(suppl 4):365.
46. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010;28:4697-4705.
47. Peeters M, Cohn A, Köhne CH et al. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. Clin Colorectal Cancer 2012;11:14-23. doi: 10.1016/j.clcc.2011.06.010.
48. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
49. Okines A, Puerto OD, Cunningham D et al. Surgery with curative-intent in patients treated with firstline chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033-1038.
50. Wong R, Cunningham D, Barbachano Y et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011;22:2042-2048.
51. Masi G, Loupakis F, Salvatore L et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: A phase 2 trial. Lancet Oncol 2010;11:845-852.
52. Kishi Y, Zorzi D, Contreras CM et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010;17:2870-2876.
53. Sullivan RD, Norcross JW, Watkins E Jr. Chemotherapy of metastatic liver cancer by prolonged hepaticartery infusion. N Engl J Med 1964;270:321-327.
54. Bouchahda M, Lévi F, Adam R et al. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. Eur J Cancer 2011;47:2681-2690.
55. Kemeny N, Huang Y, Cohen AM et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-2048.
56. Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006;20: 1161-1176, 1179; discussion 1179-1180, 1185-1186.
57. Boige V, Malka D, Elias D et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008; 15:219-226.
58. Elias D, Goere D, Boige V et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: Impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14:3188-3194.
59. Alberts SR, Sargent DJ, Smyrk TC et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. Proc Am Soc Clin Oncol 2010; 28:CRA3507.
60. Allegra CJ, Yothers G, O'Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 2011;29:11-16.
61. Andre T, Van Cutsem E, Schmoll H et al. A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. Proc Am Soc Clin Oncol 2011;29:3509.
62. Ychou M, Raoul JL, Douillard JY et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009;20: 674-680.
63. Miller AB, Hoogstraten B, StaquetMet al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
64. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
65. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-247.
66. Suzuki C, Blomqvist L, Sundin A et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 2012;23:948-954. doi: 10.1093/annonc/mdr350.
67. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19: 508-515.
68. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759.
69. Chun YS, Vauthey JN, Boonsirikamchai P et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302:2338-2344.
70. Byström P, Berglund A, Garske U et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009;20:1057-1061.
71. de Geus-Oei LF, Vriens D, van Laarhoven HW et al. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: A systematic review. J Nucl Med 2009;50(suppl 1):43S-54S.
72. Anzidei M, Napoli A, Zaccagna F et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: Evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J Comput Assist Tomogr 2011;35:690-696.
73. Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 2006;24:3939-3945.
74. Tan MC, Linehan DC, Hawkins WG et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007; 11:1112-1119.
75. Zalinski S, Abdalla EK, Mahvash A et al. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol 2009;16:1208-1211.
76. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318; discussion 318-321.
77. Rees M, Tekkis PP, Welsh FK et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: A multifactorial model of 929 patients. Ann Surg 2008;247:125-135.
78. LiverMetSurvey. International Registry of Patients Operated for Colorectal Liver Metastasis. Available at http://www.livermetsurvey.org, accessed November 23, 2011.
79. Taylor A, Kanas G, Langeberg W et al. Survival after surgical resection of hepatic metastases from colorectal cancer: A systematic review and meta-analysis. Ann Oncol 2010;21(suppl 8):632P.
80. Misiakos EP, Karidis NP, Kouraklis G. Current treatment for colorectal liver metastases. World J Gastroenterol 2011;17:4067-4075.
81. Rougier P, Milan C, Lazorthes F et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Frana̧ise de Cancérologie Digestive. Br J Surg 1995;82: 1397-1400.
82. Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am 2002;82:1075-1090.
83. Vibert E, Canedo L, Adam R. Strategies to treat primary unresectable colorectal liver metastases. Semin Oncol 2005(suppl 8);32:33-39.
84. Wicherts DA, de Haas RJ, Andreani P et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 2010;97:240-250.
85. Clavien PA, Petrowsky H, DeOliveira ML et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356:1545-1559.
86. Charnsangavej C, Clary B, Fong Y et al. Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006;13: 1261-1268.
87. Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000;231:743-751.
88. Maithel SK, Gonen M, Ito H et al. Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery 2012;151:162-170.
89. D'Angelica M, Ammori J, Gonen M et al. Folate receptor-expression in resectable hepatic colorectal cancer metastases: Patterns and significance. Mod Pathol 2011;24:1221-1228.
90. Bruin SC, He Y, Mikolajewska-Hanclich I et al. Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer 2011;105:281-287.
91. Stremitzer S, Maresch J, Aschacher T et al. Influence of KRAS status of colorectal cancer liver metastases in patients receiving neoadjuvant chemotherapy including bevacizumab prior liver resection. J Clin Oncol 2011;29(15 suppl):10620.
92. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection. Registry of Hepatic Metastases. Surgery 1988; 103:278-288.
93. Mentha G, Majno PE, Andres A et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006;93:872-878.
94. Brouquet A, Mortenson MM, Vauthey JN et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: Classic, combined or reverse strategy? J Am Coll Surg 2010;210:934-941.
95. de Jong MC, van Dam RM, MaasMet al. The liverfirst approach for synchronous colorectal liver metastasis: A 5-year single-centre experience. HPB (Oxford) 2011;13:745-752.
96. Tanaka K, Shimada H, Matsuo K et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004;136:650-659.
97. Martin R, Paty P, Fong Y et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003;197:233-241; discussion 241-242.
98. Bipat S, van Leeuwen MS, Comans EF et al. Colorectal liver metastases: CT, MRimaging, and PET for diagnosis-meta-analysis. Radiology 2005;237:123-131.
99. Adam R, Laurent A, Azoulay D et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000;232:777-785.
100. Jaeck D, Oussoultzoglou E, Rosso E et al. A twostage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004;240:1037-1049; discussion 1049-1051.
101. Wicherts DA, Miller R, de Haas RJ et al. Longterm results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008;248: 994-1005.
102. Brouquet A, Abdalla EK, Kopetz S et al. High survival rate after two-stage resection of advanced colorectal liver metastases: Response-based selection and complete resection define outcome. J Clin Oncol 2011; 29:1083-1090.
103. Reddy SK, Pawlik TM, Zorzi D et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: A multi-institutional analysis. Ann Surg Oncol 2007;14:3481-3491.
104. Ruers T, Punt CJ, van Coevorden F et al. Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). J Clin Oncol 2010;28(15 suppl):3526.
105. Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-825; discussion 825-827.
106. Aloia TA, Vauthey JN, Loyer EM et al. Solitary colorectal liver metastasis: Resection determines outcome. Arch Surg 2006;141:460-466; discussion 466-467.
107. Rubbia-Brandt L, Giostra E, Brezault C et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18:299-304.
108. Blazer DG 3rd, Kishi Y, Maru DM et al. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008;26:5344-5351.
109. Adam R, Wicherts DA, de Haas RJ et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol 2008;26:1635-1641.
110. Aloysius MM, Zaitoun AM, Beckingham IJ et al. The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: A comparative study. Virchows Arch 2007;451:943-948.
111. Ribero D, Wang H, Donadon M et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatinbased chemotherapy for colorectal liver metastases. Cancer 2007;110:2761-2767.
112. Chan G, Hassanain M, Chaudhury P et al. Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy. HPB (Oxford) 2010;12:277-284.
113. Chun YS, Laurent A, Maru D et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009;10:278-286.
114. Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-466.
115. Aloia T, Sebagh M, PlasseMet al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006;24:4983-4990.
116. Rubbia-Brandt L, Lauwers GY, Wang H et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56:430-439.
117. Fernandez FG, Ritter J, Goodwin JW et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845-853.
118. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-2072.
119. Peppercorn PD, Reznek RH, Wilson P et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998;77: 2008-2011.
120. Parikh AA, Gentner B, Wu TT et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003;7:1082-1088.
121. Bilchik AJ, Poston G, Curley SA et al. Neoadjuvant chemotherapy for metastatic colon cancer: A cautionary note. J Clin Oncol 2005;23:9073-9078.
122. Mentha G, Terraz S, Morel P et al. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg 2009; 96:95-103.
123. Holdhoff M, Schmidt K, Diehl F et al. Detection of tumor DNA at the margins of colorectal cancer liver metastasis. Clin Cancer Res 2011;17:3551-3557.
124. Kulemann V, Schima W, Tamandl D et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol 2011;79:e1-e6.
125. Goèré D, Gaujoux S, Deschamp F et al. Patients operated on for initially unresectable colorectal liver metastases with missing metastases experience a favorable long-term outcome. Ann Surg 2011;254:114-118.
126. House MG, Kemeny NE, GönenMet al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 2011; 254:851-856.
127. Tomlinson JS, Jarnagin WR, DeMatteo RP et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007;25:4575-4580.
128. Van Cutsem E, Nordlinger B, Adam R et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:2212-2221.
129. Adam R, Wicherts DA, de Haas RJ et al. Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J Clin Oncol 2009;27:1829-1835.
130. Fennell ML, Das IP, Clauser S et al. The organization of multidisciplinary care teams: Modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr 2010;2010:72-80.
131. Rabinowitz B. Interdisciplinary breast cancer care: Declaring and improving the standard. Oncology (Williston Park) 2004;18:1263-1268; discussion 1268-1270, 1275.
132. Wright FC, De Vito C, Langer B et al. Multidisciplinary cancer conferences: A systematic review and development of practice standards. Eur J Cancer 2007; 43:1002-1010.
133. Look Hong NJ, Gagliardi AR, Bronskill SE et al. Multidisciplinary cancer conferences: Exploring obstacles and facilitators to their implementation. J Oncol Pract 2010;6:61-68.
134. Jefferies H, Chan KK. Multidisciplinary team working: Is it both holistic and effective? Int J Gynecol Cancer 2004;14:210-211.
135. Davies AR, Deans DA, Penman I et al. The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer. Dis Esophagus 2006;19:496-503.
136. Fleissig A, Jenkins V, Catt S et al. Multidisciplinary teams in cancer care: Are they effective in the UK? Lancet Oncol 2006;7:935-943.
137. Gabel M, Hilton NE, Nathanson SD. Multidisciplinary breast cancer clinics. Do they work? Cancer 1997;79:2380-2384.
138. Carter S, Garside P, Black A. Multidisciplinary team working, clinical networks, and chambers; opportunities to work differently in the NHS. Qual Saf Health Care 2003;12(suppl 1):i25-i28.
139. Rummans TA, Clark MM, Sloan JA et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: A randomized controlled trial. J Clin Oncol 2006;24: 635-642.
140. Forrest LM, McMillan DC, McArdle CS et al. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005;93:977-978.
141. Birchall M, Bailey D, King P; South West Cancer Intelligence Service Head and Neck Tumour Panel. Ef-fect of process standards on survival of patients with head and neck cancer in the south and west of England. Br J Cancer 2004;91:1477-1481.
142. Westin T, Stalfors J. Tumour boards/multidisciplinary head and neck cancer meetings: Are they of value to patients, treating staff or a political additional drain on healthcare resources? Curr Opin Otolaryngol Head Neck Surg 2008;16:103-107.
143. Stephens MR, Lewis WG, Brewster AE et al. Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Dis Esophagus 2006;19:164-171.
144. Du CZ, Li J, Cai Y et al. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. World J Gastroenterol 2011; 17:2013-2018.
145. MacDermid E, Hooton G, MacDonald M et al. Improving patient survival with the colorectal cancer multi-disciplinary team. Colorectal Dis 2009;11:291-295.
146. Obias VJ, Reynolds HL Jr. Multidisciplinary teams in the management of rectal cancer. Clin Colon Rectal Surg 2007;20:143-147.
147. Devitt B, Philip J, McLachlan SA. Team dynamics, decision making, and attitudes toward multidisciplinary cancer meetings: Health professionals' perspectives. J Oncol Pract 2010;6:e17-e20.
148. Ruhstaller T, Roe H, Thr̈limann B et al. The multidisciplinary meeting: An indispensable aid to communication between different specialities. Eur J Cancer 2006;42:2459-2462.
149. McNair AG, Choh CT, Metcalfe C et al. Maximising recruitment into randomised controlled trials: The role of multidisciplinary cancer teams. Eur J Cancer 2008;44:2623-2626.
150. Siggins Miller. CanNET National Support and Evaluation Service. Final National Evaluation Report. Available at http://www.canceraustralia.gov.au/sites/default/files/user-upload/cannet/about/natl_cannet_ eval_report.pdf, accessed November 23, 2011.